106 related articles for article (PubMed ID: 21398407)
21. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
[TBL] [Abstract][Full Text] [Related]
22. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.
Romani AA; Desenzani S; Morganti MM; Baroni MC; Borghetti AF; Soliani P
Cancer Chemother Pharmacol; 2011 Mar; 67(3):557-67. PubMed ID: 20473610
[TBL] [Abstract][Full Text] [Related]
23. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines.
Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
J Neurooncol; 2014 Dec; 120(3):459-72. PubMed ID: 25139025
[TBL] [Abstract][Full Text] [Related]
24. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
Zheng L; Yang W; Zhang C; Ding WJ; Zhu H; Lin NM; Wu HH; He QJ; Yang B
Cancer Lett; 2011 Oct; 309(1):27-36. PubMed ID: 21664043
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
26. The BH3-mimetic ABT-737 inhibits allogeneic immune responses.
Cippà PE; Kraus AK; Edenhofer I; Segerer S; Chen J; Hausmann M; Liu Y; Guimezanes A; Bardwell PD; Wüthrich RP; Fehr T
Transpl Int; 2011 Jul; 24(7):722-32. PubMed ID: 21615547
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
Konopleva M; Contractor R; Tsao T; Samudio I; Ruvolo PP; Kitada S; Deng X; Zhai D; Shi YX; Sneed T; Verhaegen M; Soengas M; Ruvolo VR; McQueen T; Schober WD; Watt JC; Jiffar T; Ling X; Marini FC; Harris D; Dietrich M; Estrov Z; McCubrey J; May WS; Reed JC; Andreeff M
Cancer Cell; 2006 Nov; 10(5):375-88. PubMed ID: 17097560
[TBL] [Abstract][Full Text] [Related]
28. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma.
Lieber J; Ellerkamp V; Vogt F; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2014 Mar; 322(1):217-25. PubMed ID: 24355809
[TBL] [Abstract][Full Text] [Related]
29. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
30. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
Koyama M; Izutani Y; Goda AE; Matsui TA; Horinaka M; Tomosugi M; Fujiwara J; Nakamura Y; Wakada M; Yogosawa S; Sowa Y; Sakai T
Clin Cancer Res; 2010 Apr; 16(8):2320-32. PubMed ID: 20371690
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
34. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Jain HV; Meyer-Hermann M
Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
[TBL] [Abstract][Full Text] [Related]
35. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
[TBL] [Abstract][Full Text] [Related]
36. The BH3 mimetic ABT-737 induces cancer cell senescence.
Song JH; Kandasamy K; Zemskova M; Lin YW; Kraft AS
Cancer Res; 2011 Jan; 71(2):506-15. PubMed ID: 21084274
[TBL] [Abstract][Full Text] [Related]
37. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.
Meynet O; Zunino B; Happo L; Pradelli LA; Chiche J; Jacquin MA; Mondragón L; Tanti JF; Taillan B; Garnier G; Reverso-Meinietti J; Mounier N; Michiels JF; Michalak EM; Carles M; Scott CL; Ricci JE
Blood; 2013 Oct; 122(14):2402-11. PubMed ID: 23966420
[TBL] [Abstract][Full Text] [Related]
38. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia.
Willimott S; Beck D; Ahearne MJ; Adams VC; Wagner SD
Clin Cancer Res; 2013 Jun; 19(12):3212-23. PubMed ID: 23633452
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
[TBL] [Abstract][Full Text] [Related]
40. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation.
Gyulkhandanyan AV; Mutlu A; Allen DJ; Freedman J; Leytin V
Thromb Res; 2014 Jan; 133(1):73-9. PubMed ID: 24268298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
